WINDLASBSEWINDLAS BIOTECH LIMITED· Pharmaceuticals & BiotechnologyHighNeutral
Announced Mon, 10 Aug, 2026 · 15:23 IST

Q1 FY27 Results: Revenue up 18% YoY, PAT flat at Rs 176.5M

WINDLAS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-7.1%Reaction day
₹884.25
prior close
₹845.05
announcement price
In-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-0.1%-7.1% vs market
Pharmaceuticals peers, median of 165sector-0.1%-7.1% vs sector

On the reaction day the stock moved 7.1 pts less than Nifty Microcap 250 and 7.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-1.8
10m
—
15m
—
30m
—
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-7.1-0.1-7.1-0.1-7.1
Next day
+6.2-0.2+6.4+0.0+6.1
2d
+1.4+0.1+1.2-0.1+1.5
3d
+7.4+0.3+7.1+0.2+7.2
4d
+7.4+0.4+7.1-0.6+8.1
5d
+5.6+0.5+5.1-1.2+6.8
1w
+8.5+0.3+8.2-2.0+10.5
15d
+13.1+1.9+11.2+0.1+12.9
1m
+28.4+2.2+26.2+1.4+27.0
2m
+6.9-1.2+8.1-2.0+9.0
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Windlas Biotech reported Q1 FY27 results for quarter ended June 30, 2026. Revenue from operations rose 18.1% YoY to Rs 2,481 million from Rs 2,101 million. Profit after tax was nearly flat at Rs 176.53 million versus Rs 176.65 million a year ago, as expenses grew faster. Basic EPS was Rs 8.46. Auditor J.C. Bhalla gave an unmodified limited review. The company completed a Rs 47 crore share buyback in April 2026 and paid a Rs 6.30 per share dividend in July 2026.

Likely market impact

Revenue grew 18% YoY but profit was flat due to higher costs. Buyback and dividend are positive for shareholders.